ARBUTUS BIOPHARMA CORP (ABUS) — insider trading
Health Care · NASDAQ
ARBUTUS BIOPHARMA CORP (ABUS) has 37 reported SEC Form 4 insider transactions in our data (latest 2026-10-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Beardsley Robert A | Director | Disposition to the issuer | 17,948 | $5.00 | $89.7K | Form 4 |
| 2026-10-01 | Nguyen Tuan | Officer (Chief Financial Officer) | Disposition to the issuer | 48,081 | $5.00 | $240.4K | Form 4 |
| 2026-10-01 | Sawhney Roger | Director | Disposition to the issuer | 17,142 | $5.00 | $85.7K | Form 4 |
| 2026-10-01 | Androski Lindsay | Director, Officer (President and CEO) | Disposition to the issuer | 24,655 | $5.00 | $123.3K | Form 4 |
| 2026-10-01 | Roivant Sciences Ltd. | Director, 10% owner | Disposition to the issuer | 8,967,383 | $5.00 | $44.84M | Form 4 |
| 2026-09-18 | Nguyen Tuan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 27,475 | — | $0 | Form 4 |
| 2026-09-18 | Nguyen Tuan | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 265,625 | — | $0 | Form 4 |
| 2026-09-18 | Nguyen Tuan | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 206,637 | $5.07 | $1.05M | Form 4 |
| 2026-09-18 | Nguyen Tuan | Officer (Chief Financial Officer) | Option exercise / conversion | 27,475 | $4.39 | $120.6K | Form 4 |
| 2026-09-18 | Nguyen Tuan | Officer (Chief Financial Officer) | Option exercise / conversion | 265,625 | $3.49 | $927.0K | Form 4 |
| 2026-09-18 | Sawhney Roger | Director | Option exercise / conversion (derivative) | 78,800 | — | $0 | Form 4 |
| 2026-09-18 | Sawhney Roger | Director | Option exercise / conversion (derivative) | 52,533 | — | $0 | Form 4 |
| 2026-09-18 | Sawhney Roger | Director | Shares withheld for taxes / exercise cost | 100,508 | $5.07 | $509.6K | Form 4 |
| 2026-09-18 | Sawhney Roger | Director | Option exercise / conversion | 78,800 | $4.24 | $334.1K | Form 4 |
| 2026-09-18 | Sawhney Roger | Director | Option exercise / conversion | 52,533 | $3.34 | $175.5K | Form 4 |
| 2026-09-18 | Beardsley Robert A | Director | Option exercise / conversion (derivative) | 78,800 | — | $0 | Form 4 |
| 2026-09-18 | Beardsley Robert A | Director | Option exercise / conversion (derivative) | 52,533 | — | $0 | Form 4 |
| 2026-09-18 | Beardsley Robert A | Director | Shares withheld for taxes / exercise cost | 99,057 | $5.07 | $502.2K | Form 4 |
| 2026-09-18 | Beardsley Robert A | Director | Option exercise / conversion | 78,800 | $4.24 | $334.1K | Form 4 |
| 2026-09-18 | Beardsley Robert A | Director | Option exercise / conversion | 52,533 | $3.20 | $168.1K | Form 4 |
| 2026-09-18 | Androski Lindsay | Director, Officer (President and CEO) | Option exercise / conversion (derivative) | 10,456 | — | $0 | Form 4 |
| 2026-09-18 | Androski Lindsay | Director, Officer (President and CEO) | Option exercise / conversion (derivative) | 116,408 | — | $0 | Form 4 |
| 2026-09-18 | Androski Lindsay | Director, Officer (President and CEO) | Shares withheld for taxes / exercise cost | 82,527 | $5.07 | $418.4K | Form 4 |
| 2026-09-18 | Androski Lindsay | Director, Officer (President and CEO) | Option exercise / conversion | 10,456 | $4.39 | $45.9K | Form 4 |
| 2026-09-18 | Androski Lindsay | Director, Officer (President and CEO) | Option exercise / conversion | 116,408 | $3.20 | $372.5K | Form 4 |
| 2026-06-08 | Beardsley Robert A | Director | Grant / award / vesting (derivative) | 78,800 | — | $0 | Form 4 |
| 2026-06-08 | Sawhney Roger | Director | Grant / award / vesting (derivative) | 78,800 | — | $0 | Form 4 |
| 2026-02-02 | Androski Lindsay | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 71,700 | — | $0 | Form 4 |
| 2026-02-02 | Androski Lindsay | Director, Officer (President and CEO) | Grant / award / vesting | 28,000 | — | $0 | Form 4 |
| 2026-02-02 | Nguyen Tuan | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 188,400 | — | $0 | Form 4 |
| 2026-02-02 | Nguyen Tuan | Officer (Chief Financial Officer) | Grant / award / vesting | 73,500 | — | $0 | Form 4 |
| 2025-08-04 | Sawhney Roger | Director | Grant / award / vesting (derivative) | 157,600 | — | $0 | Form 4 |
| 2025-03-31 | Nguyen Tuan | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 750,000 | — | $0 | Form 4/A |
| 2025-03-31 | Nguyen Tuan | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 750,000 | — | $0 | Form 4 |
| 2025-03-18 | Androski Lindsay | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 310,422 | — | $0 | Form 4 |
| 2025-03-18 | Beardsley Robert A | Director | Grant / award / vesting (derivative) | 157,600 | — | $0 | Form 4 |
| 2025-03-18 | Hasija Anuj | Director | Grant / award / vesting (derivative) | 157,600 | — | $0 | Form 4 |
Ask the chat about ABUS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ARBUTUS BIOPHARMA CORP (ABUS).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.